ETIOTROPIC TREATMENT OPTIONS IN PATIENTS WITH HCV-INFECTION AND CYTOPENIA

Aim. The article aims to observe the efficiency of alternative (etiopathogenic) treatment schemes in HCV-patients with limited access to the usual doses of interferon-α caused by cytopenia and without possibility to use modern antiviral drugs of direct action. Materials and methods. Reduced doses of interferon-α with dosed by weight ribavirin and interleukin-2 were administered daily within 48 weeks. Results. Clinical manifestations improved, asthenovegetative and dyspepsial syndromes disappeared or highly reduced, liver size decreased and its function improved (biochemical response). Conclusion. The suggested treatment regimen provides a sustained viral response in 16.6% cases, improves clinical manifestations, biochemical liver function, provides a substitution immunocorrective effect by reducing immune cell-factor imbalance.

HCV-infection, etiopathogenetic therapy, cellular immunity, interleukin-2